Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.44 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.44 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4647893 | 0.85 | ALDH1A1 (0.56) | ALDH1A1HIF1ATXNRD1TXNRD3TXNRD2 | |
| SCHEMBL30648783 | 0.85 | ALDH1A1 (0.56) | ALDH1A1HIF1ATXNRD1TXNRD3TXNRD2 | |
| SCHEMBL1591294 | 0.83 | ERN1 (0.58) | ALDH1A1HIF1ATXNRD1TXNRD3TXNRD2 | |
| SCHEMBL5923822 | 0.81 | ALDH1A1 (0.52) | ALDH1A1HIF1ATXNRD1TXNRD3TXNRD2 | |
| SCHEMBL6410654 | 0.79 | ALDH1A1 (0.57) | ALDH1A1HIF1ATXNRD1TXNRD3TXNRD2 | |
| SCHEMBL30929373 | 0.79 | ALDH1A1 (0.57) | ALDH1A1HIF1ATXNRD1TXNRD3TXNRD2 | |
| SCHEMBL28017299 | 0.79 | TXNRD1 (0.46) | ALDH1A1TXNRD1TXNRD3TXNRD2ERN1 | |
| SCHEMBL13092117 | 0.79 | ALDH1A1 (0.49) | ALDH1A1HIF1ATXNRD1TXNRD3TXNRD2 | |
| SCHEMBL38663477 | 0.78 | HSD17B10 (0.60) | ALDH1A1TXNRD1TXNRD3TXNRD2ERN1 | |
| SCHEMBL526878 | 0.78 | HSD17B10 (0.60) | ALDH1A1TXNRD1TXNRD3TXNRD2ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3239150-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-10202376-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-12 | — | — | US | disclosed |
| US-20170362223-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-21 | — | — | US | disclosed |
| EP-3239150-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-11-01 | — | — | EP | disclosed |
| US-9624209-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-9624209-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-20150099728-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | MEDIFRON DBT INC. (KR) | 2015-04-09 | — | — | US | disclosed |
| US-20150099728-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | MEDIFRON DBT INC. (KR) | 2015-04-09 | — | — | US | disclosed |
| US-8946204-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946204-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| WO-2009032123-A2 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032124-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032124-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20080045493-A1 | Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-02-21 | — | — | US | disclosed |
| CN-101039904-A | Is suitable for treating dopamine D3Heterocyclic compounds for receptor-modulated responsive disorders | ABBOTT GMBH & CO KG (DE) | 2007-09-19 | — | — | CN | disclosed |
| EP-1814849-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-08-08 | — | — | EP | disclosed |
| EP-1660488-A1 | NOVEL ANTIMICROBIAL ARYLOXAZOLIDINONE COMPOUNDS | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2006040182-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-04-20 | — | — | WO | disclosed |
| US-20050065187-A1 | Novel antimicrobial aryloxazolidinone compounds | GORDEEV MIKHAIL FEDOROVICH (US) | 2005-03-24 | — | — | US | disclosed |
| WO-2005019214-A1 | NOVEL ANTIMICROBIAL ARYLOXAZOLIDINONE COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099728-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV6 | ALDH1A1 2943/4885HIF1A 1967/4885TXNRD1 3085/4885 |
| US-10202376-B2 | Heterocyclic compound | GRIN2A, GRIN1, GRIN2B | ALDH1A1 2297/4885HIF1A 3409/4885TXNRD1 3852/4885 |
| US-20080045493-A1 | Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor | DRD3, MC3R, CHRNA3 | ALDH1A1 1263/4885HIF1A 3554/4885TXNRD1 1103/4885 |
| US-20050065187-A1 | Novel antimicrobial aryloxazolidinone compounds | XDH, NQO1, MPO | ALDH1A1 723/4885HIF1A 4466/4885TXNRD1 259/4885 |
| US-20170362223-A1 | HETEROCYCLIC COMPOUND | GRIN2A, GRIN1, GRIN2B | ALDH1A1 2297/4885HIF1A 3409/4885TXNRD1 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.